Theseus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.9
- Today's High:
- $2.97
- Open Price:
- $2.95
- 52W Low:
- $2.62
- 52W High:
- $14.767
- Prev. Close:
- $3
- Volume:
- 80407
Company Statistics
- Market Cap.:
- $140.40 million
- Book Value:
- 5.388
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -17.09%
- Return on Equity TTM:
- -24.99%
Company Profile
Theseus Pharmaceuticals Inc had its IPO on 2021-10-07 under the ticker symbol THRX.
The company operates in the Healthcare sector and Biotechnology industry. Theseus Pharmaceuticals Inc has a staff strength of 38 employees.
Stock update
Shares of Theseus Pharmaceuticals Inc opened at $2.95 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.9 - $2.97, and closed at $2.96.
This is a -1.33% slip from the previous day's closing price.
A total volume of 80,407 shares were traded at the close of the day’s session.
In the last one week, shares of Theseus Pharmaceuticals Inc have slipped by -8.07%.
Theseus Pharmaceuticals Inc's Key Ratios
Theseus Pharmaceuticals Inc has a market cap of $140.40 million, indicating a price to book ratio of 1.0396 and a price to sales ratio of 0.
In the last 12-months Theseus Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-65990000. The EBITDA ratio measures Theseus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Theseus Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -17.09% with a return of equity of -24.99%.
In Q2, Theseus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Theseus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Theseus Pharmaceuticals Inc’s profitability.
Theseus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.2287. Its price to sales ratio in the trailing 12-months stood at 0.
Theseus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $245.07 million
- Total Liabilities
- $7.68 million
- Operating Cash Flow
- $-51939000.00
- Capital Expenditure
- $11000
- Dividend Payout Ratio
- 0%
Theseus Pharmaceuticals Inc ended 2024 with $245.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $245.07 million while shareholder equity stood at $234.08 million.
Theseus Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $7.68 million in other current liabilities, 4000.00 in common stock, $-141577000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $47.47 million and cash and short-term investments were $208.21 million. The company’s total short-term debt was $754,000 while long-term debt stood at $0.
Theseus Pharmaceuticals Inc’s total current assets stands at $213.75 million while long-term investments were $26.03 million and short-term investments were $160.74 million. Its net receivables were $0 compared to accounts payable of $2.42 million and inventory worth $0.
In 2024, Theseus Pharmaceuticals Inc's operating cash flow was $-51939000.00 while its capital expenditure stood at $11000.
Comparatively, Theseus Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.96
- 52-Week High
- $14.767
- 52-Week Low
- $2.62
- Analyst Target Price
- $6.75
Theseus Pharmaceuticals Inc stock is currently trading at $2.96 per share. It touched a 52-week high of $14.767 and a 52-week low of $14.767. Analysts tracking the stock have a 12-month average target price of $6.75.
Its 50-day moving average was $4.21 and 200-day moving average was $7.9 The short ratio stood at 0.99 indicating a short percent outstanding of 0%.
Around 262% of the company’s stock are held by insiders while 9705.6% are held by institutions.
Frequently Asked Questions About Theseus Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.